anthrax vaccines

Summary

Summary: Vaccines or candidate vaccines used to prevent ANTHRAX.

Top Publications

  1. ncbi Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants
    Scott Jendrek
    Building 320, SAIC Frederick Inc, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    Vaccine 21:3011-8. 2003
  2. ncbi Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain
    H C Flick-Smith
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    Microb Pathog 38:33-40. 2005
  3. ncbi Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial
    Nina Marano
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 300:1532-43. 2008
  4. ncbi Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis
    Jean Nicolas Tournier
    CRSSA, Unité Interactions Hôte Pathogène, Département de Biologie des Agents Transmissibles, BP 87, F 38702 La Tronche, France
    Expert Rev Anti Infect Ther 7:219-36. 2009
  5. ncbi A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax
    Jyotsna Gorantala
    Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India
    Vaccine 29:4521-33. 2011
  6. pmc Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities
    Tod J Merkel
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:18091-6. 2010
  7. ncbi Anthrax vaccine powder formulations for nasal mucosal delivery
    Ge Jiang
    BD Technologies, 21 Davis Dr, RTP, North Carolina 27709, USA
    J Pharm Sci 95:80-96. 2006
  8. ncbi Dr. Jekyll and Mr. Hyde: a short history of anthrax
    Maxime Schwartz
    Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France
    Mol Aspects Med 30:347-55. 2009
  9. pmc Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice
    Helen C Flick-Smith
    Dstl, Chemical and Biological Sciences, Porton Down, Salisbury, Wiltshire, SP4 0JQ, United Kingdom
    Infect Immun 70:2022-8. 2002
  10. pmc Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire
    William W Kwok
    Benaroya Research Institute at Virginia Mason, Seattle, WA 98101 2795, USA
    J Immunol 188:2537-44. 2012

Detail Information

Publications192 found, 100 shown here

  1. ncbi Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants
    Scott Jendrek
    Building 320, SAIC Frederick Inc, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    Vaccine 21:3011-8. 2003
    ..These data suggest that the interaction between rPA and aluminum hydroxide adjuvant is predominantly electrostatic in character...
  2. ncbi Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain
    H C Flick-Smith
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    Microb Pathog 38:33-40. 2005
    ..An assessment of protection in the TO mouse against aerosol challenge with the fully virulent strain of B. anthracis, Ames, was also made...
  3. ncbi Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial
    Nina Marano
    Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    JAMA 300:1532-43. 2008
    ..In 1999, the US Congress directed the Centers for Disease Control and Prevention to conduct a pivotal safety and efficacy study of anthrax vaccine adsorbed (AVA)...
  4. ncbi Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis
    Jean Nicolas Tournier
    CRSSA, Unité Interactions Hôte Pathogène, Département de Biologie des Agents Transmissibles, BP 87, F 38702 La Tronche, France
    Expert Rev Anti Infect Ther 7:219-36. 2009
    ..anthracis, which will logically lead to better vaccines (and therapeutics), there also needs to be the same level of open-mindedness applied to the politics of anthrax...
  5. ncbi A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax
    Jyotsna Gorantala
    Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi, India
    Vaccine 29:4521-33. 2011
    The currently available anthrax vaccines are limited by being incompletely characterized, potentially reactogenic and have an expanded dosage schedule. Plant based vaccines offer safe alternative for vaccine production...
  6. pmc Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities
    Tod J Merkel
    Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:18091-6. 2010
    ....
  7. ncbi Anthrax vaccine powder formulations for nasal mucosal delivery
    Ge Jiang
    BD Technologies, 21 Davis Dr, RTP, North Carolina 27709, USA
    J Pharm Sci 95:80-96. 2006
    ..In combination with noninvasive intranasal delivery, such powder formulations may offer an attractive approach for mass biodefense immunization...
  8. ncbi Dr. Jekyll and Mr. Hyde: a short history of anthrax
    Maxime Schwartz
    Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France
    Mol Aspects Med 30:347-55. 2009
    ..Infection of animals can be prevented by the administration of vaccines, the first of which was developed by Pasteur after an historical testing at Pouilly-le-Fort which marked the beginning of the science of vaccines...
  9. pmc Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice
    Helen C Flick-Smith
    Dstl, Chemical and Biological Sciences, Porton Down, Salisbury, Wiltshire, SP4 0JQ, United Kingdom
    Infect Immun 70:2022-8. 2002
    Existing licensed anthrax vaccines are administered parenterally and require multiple doses to induce protective immunity. This requires trained personnel and is not the optimum route for stimulating a mucosal immune response...
  10. pmc Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire
    William W Kwok
    Benaroya Research Institute at Virginia Mason, Seattle, WA 98101 2795, USA
    J Immunol 188:2537-44. 2012
    ..These findings implicate naive frequencies as a crucial factor in shaping the epitope specificity of memory CD4(+) T cell responses...
  11. pmc A requirement for FcγR in antibody-mediated bacterial toxin neutralization
    Nareen Abboud
    Department of Microbiology and Immunology, Division of Infectious Diseases, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    J Exp Med 207:2395-405. 2010
    ..These findings highlight a new parameter for evaluating vaccine responses and the possibility of harnessing optimal FcγR interactions in the design of passive immunization strategies...
  12. ncbi Vaccine-induced protection against anthrax in cheetah (Acinonyx jubatus) and black rhinoceros (Diceros bicornis)
    P C B Turnbull
    Arjemptur Technology, Science Park, Dstl, Porton Down, Salisbury SP4 0JQ, UK
    Vaccine 22:3340-7. 2004
    ..At least one well-separated booster does appear to be desirable. Vaccination of rhino also appears to be justified from the limited data obtained...
  13. pmc Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge
    Anna U Bielinska
    Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0648, USA
    Infect Immun 75:4020-9. 2007
    ..This potentially could lead to a needle-free anthrax vaccine requiring fewer doses and having fewer side effects than the currently available human vaccine...
  14. ncbi Anthrax capsule vaccine protects against experimental infection
    Donald J Chabot
    US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21701, USA
    Vaccine 23:43-7. 2004
    ..Surprisingly, some protection was also observed when protective antigen was conjugated to itself...
  15. pmc A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques
    Conrad P Quinn
    Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Vaccine Immunol 19:1730-45. 2012
    ..Vaccinated animals surviving inhalation anthrax developed high-magnitude anamnestic anti-PA IgG and TNA responses...
  16. ncbi Anthrax as a biological weapon, 2002: updated recommendations for management
    Thomas V Inglesby
    Johns Hopkins Center for Civilian Biodefense Strategies, Johns Hopkins University, Baltimore, MD 21202, USA
    JAMA 287:2236-52. 2002
    ..To review and update consensus-based recommendations for medical and public health professionals following a Bacillus anthracis attack against a civilian population...
  17. ncbi Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms
    John A Mikszta
    BD Technologies, 21 Davis Dr, Research Triangle Park, NC 27709, USA
    J Infect Dis 191:278-88. 2005
    ..The novel vaccine/device combinations described here have the potential to improve the efficacy of rPA and other biodefense vaccines...
  18. pmc Anthrax spores make an essential contribution to vaccine efficacy
    Fabien Brossier
    Unité des Toxines et Pathogénie Bactérienne CNRS URA 2172, Institut Pasteur, 75725 Paris Cedex 15, France
    Infect Immun 70:661-4. 2002
    ..Guinea pigs and mice had very different susceptibilities to infection with the nontoxigenic strain, highlighting the importance of verifying the pertinence of animal models for evaluating anthrax vaccines.
  19. ncbi Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin
    P F Fellows
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 19:3241-7. 2001
    ..These studies demonstrated that, although AVA confers variable protection against different B. anthracis isolates in guinea pigs, it is highly protective against these same isolates in both rabbits and rhesus macaques...
  20. pmc Rabies virus glycoprotein as a carrier for anthrax protective antigen
    Mary Ellen Smith
    Department of Microbiology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Virology 353:344-56. 2006
    ..These data demonstrate that a viral envelope protein can carry a bacterial protein and that a viral carrier can display whole polypeptides compared to the limited epitope presentation of previous viral systems...
  21. pmc Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization
    Kenneth Smith
    Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA
    Vaccine 30:4276-83. 2012
    ..These fully human antibodies provide insight into the neutralizing response to AVA for future subunit vaccine and passive immunotherapeutic cocktail design...
  22. pmc Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge
    Helen S Garmory
    Defence Science and Technology Laboratory, Salisbury SP4 0JQ, United Kingdom
    Infect Immun 71:3831-6. 2003
    ..These mice were protected against intraperitoneal challenge with 100 or 1,000 50% lethal doses of B. anthracis strain STI. This work contributes to the development of a Salmonella-based orally delivered anthrax vaccine...
  23. pmc Development of an improved vaccine for anthrax
    Stephen H Leppla
    National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland 20892 4350, USA
    J Clin Invest 110:141-4. 2002
  24. pmc Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen
    Kristina K Peachman
    Department of Vaccine Production and Delivery, Division of Retrovirology, U S Military HIV Research Program, Walter Reed Army Institute of Research, 1600 East Gude Drive, Rockville, MD 20850, USA
    Infect Immun 74:794-7. 2006
    ..Future experiments with rabbits and nonhuman primates should confirm the significance of protection by this vaccine strategy...
  25. ncbi Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine
    S F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 22:422-30. 2004
    ..0015) of protection against a B. anthracis aerosol spore challenge in rabbits...
  26. pmc Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity
    Sherry R Crowe
    Oklahoma Medical Research Foundation, 825 N E 13th Street, Oklahoma City, OK 73104, USA
    Vaccine 29:3670-8. 2011
    ..Findings from these studies have important implications for vaccine design and immunotherapeutic development...
  27. ncbi Long-lasting T cell responses to biological warfare vaccines in human vaccinees
    Jennifer S Allen
    Department of Immunobiology, School of Medicine, King s College London School of Medicine, London, United Kingdom
    Clin Infect Dis 43:1-7. 2006
    ....
  28. ncbi In vitro correlate of immunity in a rabbit model of inhalational anthrax
    M L Pitt
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 19:4768-73. 2001
    ..Results showed that antibody levels to PA at both 6 and 10 weeks were significant (P<0.0001) predictors of survival...
  29. ncbi Anthrax toxin: a tripartite lethal combination
    Paolo Ascenzi
    Department of Biology and Interdepartmental Laboratory for Electron Microscopy, University Roma Tre, Viale G Marconi 446, 00146, Rome, Italy
    FEBS Lett 531:384-8. 2002
    ..Inhibitors targeting different steps of toxin activity have recently been developed. Anthrax toxin has also been exploited as a therapeutic agent against cancer...
  30. ncbi Molecular basis for improved anthrax vaccines
    Robert N Brey
    DOR BioPharma, Inc, 1691 Michigan Avenue, Suite 435, Miami, FL 33139, USA
    Adv Drug Deliv Rev 57:1266-92. 2005
    ..The next generation anthrax vaccines will be derived from the thorough understanding of the interaction of virulence factors with human and animal ..
  31. pmc Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits
    Shay Weiss
    Department of Infectious Diseases, Israel Institute for Biological Research, P O Box 19, Ness Ziona, Israel 74100
    Infect Immun 74:394-8. 2006
    ..In conclusion, this study emphasizes that regardless of the immunization regimen or the time of challenge, neutralizing antibody titers are better predictors of protection than total anti-PA titers...
  32. pmc A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed
    Nicholas M Pajewski
    Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston Salem, NC 27157 1063, USA
    Vaccine 30:4778-84. 2012
    ..032). Future studies will be required to replicate these findings in European Americans and to further elucidate the host genetic factors underlying variable immune response to AVA...
  33. pmc The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed
    N M Pajewski
    Section on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
    Genes Immun 12:457-65. 2011
    ..Further studies will be required to replicate these findings and to explore the role of host genetic variation outside of the HLA region...
  34. ncbi Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes
    Rebecca J Ingram
    Department of Infectious Diseases and Immunity, Imperial College London, London, United Kingdom
    J Immunol 184:3814-21. 2010
    ..Although serological responses to existing anthrax vaccines focus primarily on protective Ag, the major target of T cell immunity in infected individuals and anthrax-..
  35. ncbi Past, imminent and future human medical countermeasures for anthrax
    L W J Baillie
    Biodefence Initiative, Medical Biotechnology Center, University of Maryland Biotechnology Institute, Baltimore, 21201, USA
    J Appl Microbiol 101:594-606. 2006
    ..This brief review will describe the efforts being made to address these issues...
  36. ncbi Key roles of dendritic cells in lung infection and improving anthrax vaccines
    Jean Nicolas Tournier
    Unité Interactions Hôte Agents Pathogènes, Departement de Microbiologie, Institut de Recherche Biomédicale des Armées, La Tronche, France
    Trends Mol Med 16:303-12. 2010
    ..anthracis infection and its effects on lung immune mechanisms. Vaccines strategies that mobilize protective mucosal and systemic immunity against this deadly microbe are highlighted...
  37. ncbi Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis
    Ian Justin Glomski
    Unité des Toxines et Pathogénie Bactérienne, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
    J Immunol 178:2646-50. 2007
    ..These results are the first evidence of protective cellular immunity against capsulated B. anthracis and suggest that future antianthrax vaccines should strive to augment cellular adaptive immunity...
  38. pmc Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species
    Kristian S Omland
    Precision Bioassay, Burlington, Vermont, USA
    Clin Vaccine Immunol 15:946-53. 2008
    ..lethal toxin neutralization assay (TNA) will likely be used to correlate the protection offered by new anthrax vaccines in animal models to the immunogenicity that will be provided in humans...
  39. pmc Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant
    Leslie Wagner
    Center for Biologics Evaluation and Research, Food and Drug Administration Bethesda, MD, USA
    Clin Vaccine Immunol 19:1465-73. 2012
    New anthrax vaccines currently under development are based on recombinant protective antigen (rPA) and formulated with aluminum adjuvant...
  40. ncbi Detection of anthrax vaccine virulence factors by polymerase chain reaction
    A Fasanella
    Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata, Via Manfredonia 20, 71100, Foggia, Italy
    Vaccine 19:4214-8. 2001
    ..This study showed that the 'Carbosap' vaccine strain has a different plasmid pattern in comparison to Pasteur vaccine strain SS104 and Sterne vaccine strain F34...
  41. ncbi Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG
    V A Semenova
    Centers for Disease Control and Prevention CDC, 1600 Clifton Rd, Atlanta, GA 30333, USA
    J Immunol Methods 376:97-107. 2012
    ..is essential for comparative analyses of anti-toxin immune responses in anthrax cases, recipients of PA-based anthrax vaccines and for evaluation of anti-PA based immunotherapies...
  42. pmc Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy
    Leslie W J Baillie
    Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, Wales, United Kingdom
    Vaccine 26:6083-91. 2008
    ..The results of this study demonstrate the feasibility of employing a mucosal prime with a licensed Salmonella Typhi vaccine strain followed by a parenteral protein boost to stimulate rapid protective immunity against anthrax...
  43. ncbi Validation of the anthrax lethal toxin neutralization assay
    Donna Hering
    Product Development and Regulatory Affairs, US Army Medical Research Institute of Infectious Diseases 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Biologicals 32:17-27. 2004
    ..The work was performed in accordance with the FDA's Bioanalytical Method Validation Guidance for Industry and the FDA's Good Laboratory Practice for Nonclinical Laboratory Studies (21 CFR Part 58)...
  44. pmc Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways
    William A Langley
    Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, Atlanta, Georgia 30322, USA
    J Virol 84:8300-7. 2010
    ..In some cases, such toxin-neutralizing activity was notably high, indicating that the mechanisms by which immunity is primed by live influenza virus vectors may have beneficial properties...
  45. ncbi Evaluation of immune response to orally administered Sterne strain 34F2 anthrax vaccine
    Krishna P Shakya
    Louisiana State University, School of Veterinary Medicine, Department of Pathobiological Sciences, Skip Bertman Dr, Baton Rouge, LA 70803, United States
    Vaccine 25:5374-7. 2007
    ....
  46. pmc Anthrax vaccination strategies
    Robert J Cybulski
    Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, United States
    Mol Aspects Med 30:490-502. 2009
    ..anthracis organism, are under active investigation. This review seeks to summarize work that has been done to build on the current PA-based vaccine methodology and to evaluate the search for future anthrax prophylaxis strategies...
  47. ncbi Advances in the development of next-generation anthrax vaccines
    Arthur M Friedlander
    United States Army Medical Research Institute of Infectious Diseases, Headquarters, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Vaccine 27:D28-32. 2009
    ..Attempts to broaden the protection afforded by PA-based vaccines have focused on adding other B. anthracis components, including spore and capsule antigens...
  48. ncbi Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines
    P M Parreiras
    Oswaldo Cruz Foundation, Research Center Rene Rachou, Av Augusto de Lima 1715, Belo Horizonte, MG 30190 002, Brazil
    Vaccine 27:4537-42. 2009
    ..of lethal challenge models have prompted the investigation of immunogenicity assays as potency tests of anthrax vaccines. An ELISA and a lethal toxin neutralization assay (TNA) were used to measure antibody response to Protective ..
  49. ncbi 2-D reference map of Bacillus anthracis vaccine strain A16R proteins
    Junjun Wang
    State Key Laboratory of Pathogens and Biosecurity, Beijing, China
    Proteomics 5:4488-95. 2005
    ..Maps and information about all identified proteins are available on the Internet at http://www.mpiib-berlin.mpg.de/2D-PAGE and http://www.proteomics.com.cn...
  50. ncbi Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109
    Mili Gu
    Emergent BioSolutions, 300 Professional Drive, Gaithersburg, MD 20879, USA
    Vaccine 25:526-34. 2007
    ....
  51. ncbi Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice
    S F Little
    United States Army Medical Research Institute of Infectious Disease, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Biologicals 32:62-9. 2004
    ....
  52. ncbi Anthrax vaccines: Pasteur to the present
    A Scorpio
    Bacteriology Division, United States Army Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, Maryland 21701, USA
    Cell Mol Life Sci 63:2237-48. 2006
    ..Due to animal vaccinations, the rate of infection has dropped dramatically. Anthrax vaccines have progressed from uncharacterized whole-cell vaccines in 1881, to pXO2-negative spores in the 1930s, to ..
  53. ncbi Characterisation of adsorbed anthrax vaccine by two-dimensional gel electrophoresis
    G C Whiting
    Division of Bacteriology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Vaccine 22:4245-51. 2004
    ..The use of proteomics can provide useful information on the antigenic make up of this vaccine and the consistency of vaccine production...
  54. ncbi Anthrax vaccines
    Miroslav Splino
    Department of Epidemiology, Military Medical Academy, Hradec Kralove, Czech Republic
    Ann Saudi Med 25:143-9. 2005
    ..In Russia, live spore vaccine (STI) has been used in a two-dose schedule. Current anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever)...
  55. pmc Multicomponent anthrax toxin display and delivery using bacteriophage T4
    Sathish B Shivachandra
    Department of Biology, 103 McCort Ward Hall, The Catholic University of America, 620 Michigan Ave, NE, Washington, DC 20064, USA
    Vaccine 25:1225-35. 2007
    ..These features offer novel avenues to develop customized multicomponent vaccines against anthrax and other pathogenic diseases...
  56. pmc Immunologic response of unvaccinated workers exposed to anthrax, Belgium
    Pierre Wattiau
    Veterinary and Agro chemical Research Centre, Department of Bacterial Diseases, Brussels, Belgium
    Emerg Infect Dis 15:1637-40. 2009
    ..Of 66 workers, approximately 10% had circulating antibodies or T lymphocytes that reacted with anthrax protective antigen. Individual immunity varied from undetectable to high...
  57. pmc A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection
    Helen C Flick-Smith
    Dstl, Chemical and Biological Sciences, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Infect Immun 70:1653-6. 2002
    ..Results show that protection can be attributed to individual domains and imply that it is domain 4 which contains the dominant protective epitopes of PA...
  58. pmc Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background
    Nareen Abboud
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA
    Clin Vaccine Immunol 15:1115-23. 2008
    ..The results suggest that the variability observed in vaccination studies with PA-derived vaccines is a result of host heterogeneity and implies a need to develop other antigens as vaccine candidates...
  59. pmc A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores
    G Hermanson
    Vical Inc, San Diego, CA 92121, USA
    Proc Natl Acad Sci U S A 101:13601-6. 2004
    ..Preclinical evaluation of this cationic lipid-formulated bivalent PA and LF vaccine is complete, and the vaccine has received U.S. Food and Drug Administration Investigational New Drug allowance...
  60. ncbi Adverse medical events in British service personnel following anthrax vaccination
    Joanne E Enstone
    Division of Public Health Sciences, University of Nottingham Medical School, Queen s Medical Centre, UK
    Vaccine 21:1348-54. 2003
    ..The anthrax vaccine resulted in mild side-effects in 11%, and no serious side-effects were observed. Acceptors of vaccine did not have significantly more medical consultations following vaccination than their unvaccinated counterparts...
  61. ncbi Is new always better than old?: The development of human vaccines for anthrax
    Leslie W Baillie
    Welsh School of Pharmacy, Cardiff University, Wales, UK
    Hum Vaccin 5:806-16. 2009
    ..If we are to respond effectively to emerging biological threats we need to develop processes that generate protective vaccines in a meaningful time frame and yield products in months not decades!..
  62. ncbi Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5033, USA
    Vaccine 24:2530-6. 2006
    ..Neither gender nor challenge dose were identified as having a statistically significant effect on survival. Booster vaccinations with rPA may be required for the long-term protection of rabbits against anthrax...
  63. pmc Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax
    E D Williamson
    Defence Science and Technology Laboratory Porton Down, Salisbury, Wilts SP4 0JQ, United Kingdom
    Infect Immun 73:5978-87. 2005
    ..anthracis. These data provide some preliminary evidence for the existence of immune correlates of protection against anthrax infection in rhesus macaques immunized with rPA...
  64. ncbi Bacillus anthracis: balancing innocent research with dual-use potential
    Michael J Hudson
    Health Protection Agency, Porton Down, Salisbury, UK
    Int J Med Microbiol 298:345-64. 2008
    ..networking activities between anthrax research groups in Europe and to harmonise protocols for testing anthrax vaccines and therapeutics...
  65. ncbi Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)
    John L Sever
    Departments of Pediatrics, Obstetrics and Gynecology, Microbiology and Immunology, Children s National Medical Center, George Washington University, School of Medicine, 111 Michigan Avenue, N W, Washington, DC 20010 2970, USA
    Pharmacoepidemiol Drug Saf 11:189-202. 2002
    ..To assess the safety of a licensed anthrax vaccine given to nearly 400,000 US military personnel, reports of adverse events (AEs) submitted to the Vaccine Adverse Event Reporting System (VAERS) were reviewed and evaluated medically...
  66. ncbi Development of an in vitro-based potency assay for anthrax vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5033, USA
    Vaccine 22:2843-52. 2004
    ..An advantage of the proposed in vitro-based potency assay is that it will not need stringent biosafety containment measures as required by the current guinea pig potency assay...
  67. pmc An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor
    Les W Baillie
    Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK
    Vaccine 28:6740-8. 2010
    Studies have confirmed the key role of Bacillus anthracis protective antigen (PA) in the US and UK human anthrax vaccines. However, given the tripartite nature of the toxin, other components, including lethal factor (LF), are also likely ..
  68. pmc The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells
    William W Kwok
    Benaroya Research Institute, Seattle, WA 98101, USA
    Infect Immun 76:4538-45. 2008
    ..The data also demonstrated the feasibility of using class II tetramers to analyze CD4(+) cell responses and lineage development after vaccination...
  69. ncbi Recent progress in the development of anthrax vaccines
    Manpreet Kaur
    Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India
    Recent Pat Biotechnol 5:148-59. 2011
    ..A number of approaches are being investigated to substitute or supplement the existing anthrax vaccines. These relied on expression of Protective antigen (PA), the key protective immunogen; in bacterial or plant ..
  70. ncbi An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals
    John F Hewetson
    United States Army Medical Research Institute of Infections Diseases USAMRIID, Fort Detrick, MD 21702, United States
    Vaccine 26:4262-6. 2008
    ..This analytical method may provide additional opportunities to compare the efficacy of improved anthrax vaccines with the licensed vaccine.
  71. pmc Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis
    Margaret G M Stokes
    Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom
    Infect Immun 75:1827-34. 2007
    ..Thus, we demonstrate for the first time the efficacy of an oral S. enterica-based vaccine against aerosolized B. anthracis spores...
  72. pmc Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults
    Bruce K Brown
    United States Military HIV Research Program, Henry M Jackson Foundation, Rockville, Maryland, United States of America
    PLoS ONE 5:e13849. 2010
    ..In this report we describe a phase I clinical trial testing the safety and immunogenicity of an anthrax vaccine using recombinant Escherichia coli-derived, B. anthracis protective antigen (rPA)...
  73. pmc Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies
    Melissa L Nguyen
    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Infect Immun 77:162-9. 2009
    ..This study paves the way for a more effective anthrax vaccine by identifying discontinuous peptide epitopes of LF...
  74. pmc Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines
    Andrew J Phipps
    Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210 1093, USA
    Microbiol Mol Biol Rev 68:617-29. 2004
    ..This article reviews the efficacy and immunogenicity of human anthrax vaccines in well-defined animal models and the progress toward developing a rugged immunologic correlate of protection...
  75. pmc The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes
    Melissa L Nguyen
    Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    Infect Immun 77:4714-23. 2009
    ..This work increases understanding of the immunogenicity of EF and LF and offers perspective for the development of new strategies for vaccination against anthrax...
  76. pmc Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein
    B M Price
    Department of Microbiology, The Ohio State University, Columbus, Ohio 43017-1292
    Infect Immun 69:4509-15. 2001
    ..These results demonstrate that DNA-based immunization alone can provide protection against a lethal toxin challenge and that DNA immunization against the LF antigen alone provides complete protection...
  77. pmc Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine
    Elsa M Laughlin
    Benaroya Research Institute at Virginia Mason, 1201 Ninth Avenue, Seattle, WA 98101, USA
    Infect Immun 75:1852-60. 2007
    ..Specific tetramer-derived T-cell profiling may be useful for monitoring helper CD4+ T-cell responses to anthrax vaccination...
  78. ncbi The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions
    C K Cote
    United States Army Medical Research Institute of Infectious Disease USAMRIID, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA
    Microb Pathog 38:209-25. 2005
    ..Thus, anti-PA Ab-mediated, anti-spore activities may play a role in protection during the early stages of an anthrax infection...
  79. pmc Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen
    Orit Gat
    Israel Institute for Biological Research, P O Box 19, Ness Ziona 74100, Israel
    Infect Immun 74:3987-4001. 2006
    ..We list more than 30 novel B. anthracis immunoreactive virulence-related proteins which could be useful in diagnosis, pathogenesis studies, and future anthrax vaccine development...
  80. pmc Expression of Bacillus anthracis protective antigen in transgenic chloroplasts of tobacco, a non-food/feed crop
    Jennifer Watson
    Department of Molecular Biology and Microbiology, University of Central Florida, Biomolecular Science Building 20, Room 336, Orlando, FL 32816 2364, USA
    Vaccine 22:4374-84. 2004
    ....
  81. pmc Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge
    Vijay Koya
    Dept Molecular Biology and Microbiology, Biomolecular Science Bldg 20, Room 336, University of Central Florida, Central Florida Blvd, Orlando, FL 32816 2364, USA
    Infect Immun 73:8266-74. 2005
    ..These results demonstrate the immunogenic and immunoprotective properties of plant-derived anthrax vaccine antigen...
  82. ncbi Adenovirus-based prime-boost immunization for rapid vaccination against anthrax
    Michael J McConnell
    Department of Microbiology and Immunology and Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Mol Ther 15:203-10. 2007
    ..These results demonstrate that adenovirus-based prime-boost vaccination can provide rapid protection from anthrax and that this approach may be an effective strategy for immunizing against bacterial as well as viral pathogens...
  83. ncbi Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series
    Phillip R Pittman
    United States Army Medical Research Institute of Infectious Disease USAMRIID, Fort Detrick, MD 21702, United States
    Vaccine 24:3654-60. 2006
    ..The 6-month dose in the AVA primary series appears to be critical in sustaining IgG to PA concentrations in a substantial proportion of recipients...
  84. ncbi Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine
    Roland Grunow
    Institut fuer Mikrobiologie der Bundeswehr, D 80937 Munich, Germany
    Vaccine 25:3679-83. 2007
    The human anthrax vaccines currently licensed contain the protective antigen (PA) of Bacillus anthracis as main antigen together with traces of some other bacillus components, e.g. lethal factor (LF)...
  85. ncbi Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial
    Geoffrey J Gorse
    Saint Louis Veterans Affairs Medical Center and St Louis University School of Medicine, St Louis, MO, USA
    Vaccine 24:5950-9. 2006
    ..We report the results of a phase I dose escalation, safety and immunogenicity trial of a new recombinant protective antigen (rPA102) anthrax vaccine...
  86. ncbi Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959]
    Thomas K Zink
    Vaccine 25:2766-7. 2007
    ....
  87. ncbi The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics
    Denise L Doolan
    Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    J Infect Dis 195:174-84. 2007
    ..Bioterrorism-related anthrax exposures occurred at the US Capitol in 2001. Exposed individuals received antibiotics and anthrax vaccine adsorbed immunization...
  88. ncbi Anthrax vaccines
    A M Friedlander
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA
    Curr Top Microbiol Immunol 271:33-60. 2002
    The only impetus for the development of new anthrax vaccines is to protect humans against the intentional use of Bacillus anthracis as a bioterrorist or warfare agent...
  89. ncbi Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007
    Manette T Niu
    Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, Division of Epidemiology, Vaccine Safety Branch, 1401 Rockville Pike, HFM 220, Rockville, MD 20852, United States
    Vaccine 27:290-7. 2009
    ..Continued monitoring of VAERS and analysis of potential associations between AVA vaccination and rare, serious events is warranted...
  90. ncbi Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
    Hum Vaccin 3:205-11. 2007
    ..Although an anthrax vaccine is currently licensed in the USA, better vaccines are desirable for both pre- and post-exposure prophylaxis...
  91. ncbi Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7"
    Geoffrey J Gorse
    Vaccine 25:7285-7. 2007
  92. ncbi Immunisation with anthrolysin O or a genetic toxoid protects against challenge with the toxin but not against Bacillus anthracis
    Graeme J M Cowan
    Division of Infection and Immunity, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow G12 8TA, UK
    Vaccine 25:7197-205. 2007
    ..Histopathological investigation following lethal i.v. challenge with ALO revealed acute pathology in the lungs with occlusion of alveolar vessels by fibrin deposits...
  93. ncbi Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen
    Le H Duc
    Royal Holloway University of London, Egham, Surrey TW20 0EX, UK
    Vaccine 25:346-55. 2007
    ..Intracellular expression of PA failed to confer protective immunity. The highest levels of protective immunity were achieved when PA was displayed on the spore surface as well as in the germinating spore...
  94. ncbi Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine
    Wendy A Keitel
    Baylor College of Medicine, Molecular Virology and Microbiology and Medicine, Room 221 D One Baylor Plaza, Houston, TX 77030, USA
    Expert Rev Vaccines 5:417-30. 2006
    ..Future licensure of these and other candidate vaccines will depend on their safety and immunogenicity profiles in humans, and their ability to confer protection in animal models of inhalational anthrax...
  95. ncbi Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses
    Yongxin Zhang
    MithraGen, Inc, 8030 El Rio, Houston, TX 77054, USA
    Vaccine 26:614-22. 2008
    ..The results demonstrate that anthrax antigens other than PA might be suitable for the generation of durable immune responses against anthrax...
  96. pmc Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity
    Laura Vitale
    Medarex, Inc, Bloomsbury, New Jersey 08804, USA
    Infect Immun 74:5840-7. 2006
    ..neutralizing antibody response to the protective antigen (PA) component of anthrax toxin elicited by approved anthrax vaccines is an accepted correlate for vaccine-mediated protection against anthrax...
  97. pmc Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines
    Benedikt A Aulinger
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, 181 Longwood Avenue, Boston, MA 02115, USA
    Infect Immun 73:3408-14. 2005
    ..In the present report, we describe the improved potency of anthrax vaccines through the use of a dominant-negative inhibitory (DNI) mutant to replace PA in PA or PA-PGA vaccines...
  98. ncbi Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants
    Inge Berthold
    Center for Biologics Evaluation and Research, US FDA, CBER DBPAP HFM 443, 1401 Rockville Pike, Rockville, MD 20852, USA
    Vaccine 23:1993-9. 2005
    ....
  99. pmc Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant
    Yong Sung Park
    Laboratory of Infection and Immunology, Graduate School of Medicine, Korea University, Seoul, South Korea
    Infect Immun 76:1952-9. 2008
    ..Thus, DNA vaccines encoding CRT linked to PA(dIV) may dramatically enhance PA-specific protective antibody responses. Our results have significant clinical applications for biodefense against anthrax toxin...
  100. ncbi Learning from the 2001 anthrax attacks: immunological characteristics
    James L Hadler
    J Infect Dis 195:163-4. 2007
  101. ncbi Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization
    Han Li
    Microbial Pathogenesis and Immune Response Laboratory, Meningitis and Vaccine Preventable Diseases Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, United States
    J Immunol Methods 333:89-106. 2008
    ..lethal toxin (LTx) neutralization activity (TNA) is pivotal in assessing protective antibody responses to anthrax vaccines and for evaluation of immunotherapies for anthrax...

Research Grants49

  1. Multivalent Plague, Anthrax Vaccines Using Bacteriophage T4 Display
    Venigalla B Rao; Fiscal Year: 2013
    ..major goal of this proposal is to test this hypothesis and develop trivalent plague and multivalent plague-anthrax vaccines that can confer protection against Bacillus anthracis and Yersinia pestis, two Category A biodefense ..
  2. Conjugate Anthrax Vaccine with Dual Virulence Factor Specificity
    Lallan Giri; Fiscal Year: 2013
    ..The currently licensed Anthrax Vaccine Adsorbed (AVA) or rPA based anthrax vaccines only address the toxin-induced disease, not the capsule mediated virulence...
  3. Designing Potent Anthrax Vaccine with Engineered Protective Antigen
    Julia Y Wang; Fiscal Year: 2010
    The long-term goal of our research is to develop potent and safe anthrax vaccines and to understand the fundamental mechanisms of anthrax toxicity and the response of the immune system to anthrax infection...
  4. Anthrax vaccination by targeting spore germination
    Chun Ming Huang; Fiscal Year: 2005
    ..That system will be used in this study to develop anthrax vaccines that will specifically target two of the germination-associated proteins: immune inhibitor A and camelysin...
  5. NOVEL IMMUNIZATION STRATEGIES AGAINST ANTHRAX
    LUCY FREYTAG; Fiscal Year: 2006
    ..understanding of the host responses involved in protection against anthrax and to the formulation of improved anthrax vaccines. This information may also be valuable in the development of similar prevention strategies against other ..
  6. Killed Rhabdoviruses as Novel Anthrax Vaccines
    Matthias Schnell; Fiscal Year: 2006
    ..Lastly, Anthrax challenge experiments of the most promising constructs in mice will indicate if the inducted responses are protective against Anthrax infection. ..
  7. Live Attenuated Bacterial Vaccines Against Anthrax
    SIMS KOCHI; Fiscal Year: 2002
    ..of live, attenuated strains of Vibrio cholerae and Salmonella typhimurium expressing PA, as improved anthrax vaccines. The Specific Aims of this project are to (1) construct attenuated V. cholerae and S...
  8. Technologies to Advance Next Generation Anthrax Vaccines
    HOWARD TRANRER; Fiscal Year: 2012
    ..abstract_text> ..
  9. Transcutaneous Immunization for an Anthrax Vaccine
    Richard Kenney; Fiscal Year: 2003
    ..with recombinant Protective Antigen from Bacillus anthracis, which is the principal component of existing anthrax vaccines and the lead candidate for a second-generation parenteral vaccine...
  10. Vaccine hurdle to anthrax and the emerging immune system
    Pranela Rameshwar; Fiscal Year: 2006
    ..This study will also form the basis to develop in vivo model with human hematopoietic system to study anthrax infection and also to improve responses to anthrax vaccines.
  11. Adenovirus-vectored nasal anthrax vaccine
    DE CHU TANG; Fiscal Year: 2005
    The aim of this proposal is to develop a new class of anthrax vaccines that can be produced rapidly and mass-administered by non-medical personnel during an emergency...
  12. Non-Invasive Plant Virus Particle-Based Anthrax Vaccines
    William Anderson; Fiscal Year: 2006
    ..The partnership, in collaboration with NIH scientists offers advancement of this novel technology platform and ultimate commercialization of new vaccines of public health importance. [unreadable] [unreadable]..
  13. T cell immunity to B. anthracis
    Zheng Chen; Fiscal Year: 2005
    ..One of the biodefense research priorities is to develop improved anthrax vaccines. Cell-mediated immune responses may play an important role in vaccine-induced protection against anthrax...
  14. Molecularly Targeted Vaccines for Anthrax
    Kemp Cease; Fiscal Year: 2007
    ..Through this approach we will develop promising candidate anthrax vaccines that can protect against currently existing strains of anthrax as well as new and enhanced threats based on ..
  15. Noninvasive delivery of skin-targeted anthrax vaccines
    DE CHU TANG; Fiscal Year: 2001
    DESCRIPTION (Provided by Applicant): Our aim is to develop a simple method for the delivery of anthrax vaccines by topical application of adenovirus-based expression vectors using a skin patch in a noninvasive mode...
  16. Rational Anthrax Vaccine with Structural Epitopes on VLP
    VSEVOLOD KATRITCH; Fiscal Year: 2002
    ..We propose to design and develop next generation recombinant anthrax vaccines with intrinsic adjuvant capabilities, based on multiple presentation of PA epitopes on the surface of self-..
  17. Structural determinants of human immunity to anthrax
    Donald Reason; Fiscal Year: 2008
    ..anthracis infection. In addition, the antibodies isolated will constitute a panel of fully human monoclonal binding domains with potential for therapeutic use as passive immunogens. [unreadable] [unreadable] [unreadable]..
  18. Human monoclonal panel mimicking anthrax immune globulin
    Donald Reason; Fiscal Year: 2005
    ..The PA-specific panel we construct will be molecularly defined and characterized, incorporate the advantages of toxin-specific, polyclonal human sera, and lack the inherent risk associated with blood derived products. ..
  19. MOLECULAR DETERMINANTS OF HUMAN PNEUMOCOCCAL IMMUNITY
    Donald Reason; Fiscal Year: 2004
    ..Understanding the molecular mechanisms that shape the human antibody repertoire to pneumococcal polysaccharides may also suggest strategies that would facilitate the development of more efficacious vaccines. ..
  20. Preclinical Development of Non-Invasive Anthrax Vaccine
    SUSAN WIMER; Fiscal Year: 2005
    ....
  21. Neurotoxicity of sterol glucosides: role in ALS-PDC
    Christopher Shaw; Fiscal Year: 2008
    ..Our long-term Aims are to identify the causative molecule(s) in ALS-PDC which can share common basis with the rest of the neurodegenerative diseases. [unreadable] [unreadable] [unreadable]..
  22. New genetic vaccine to protect aganist botulism
    Mingtao Zeng; Fiscal Year: 2004
    ..Specific Aim #2: To study the mucosal and systemic immunity elicited by the vectored vaccine developed in aim #1 through intranasal and transcutaneous immunization in a mouse model. ..
  23. Anthrax DNA vaccine for non-invasive immunization on skin
    Zhengrong Cui; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  24. Continued Development of a Recombinant Vaccine (RivaxTM) against Ricin Toxin
    Robert Brey; Fiscal Year: 2008
    ..A safe and effective FDA-approved vaccine is urgently needed for military personnel and, in the event of a domestic attack, for first responders and perhaps for the general public. [unreadable] [unreadable] [unreadable]..
  25. A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli
    Zhengrong Cui; Fiscal Year: 2008
    ..The same vaccine or its modified version can also be used in agricultural industries to vaccinate cattle. [unreadable] [unreadable] [unreadable]..
  26. Regulation of plasma cell differentiation by PI3-kinase
    ROBERT RICKERT; Fiscal Year: 2008
    ..Hence, understanding the pathways regulating these processes is a requisite step towards our ability to understand the etiology of these diseases. [unreadable] [unreadable] [unreadable] [unreadable]..
  27. Phospholipid signaling in B Lymphocytes
    ROBERT RICKERT; Fiscal Year: 2009
    ..Through the generation and characterization of these mice we will learn how PI3K directs B cell differentiation, and provide insight into how such regulation can go awry in the case of B cell transformation. ..
  28. Statistical Models for Anthrax
    Ronald Brookmeyer; Fiscal Year: 2003
    ..This work will depend on results from specific aims 1 and 2. ..
  29. MICROSPHERE VACCINE AGAINST AEROSOLIZED RICIN TOXIN
    Robert Brey; Fiscal Year: 2003
    ..abstract_text> ..
  30. TRANSCUTANEOUS IMMUNIZATION FOR TETANUS BOOSTER
    Gregory Glenn; Fiscal Year: 2003
    ..Additionally, the Transcutaneous booster will decrease the risk of needle-sticks and related disease, and reduce personnel and equipment requirements related to tetanus immunization. ..
  31. DEVELOPMENT OF A RECOMBINANT VACCINE FOR RICIN TOXIN
    Robert Brey; Fiscal Year: 2004
    ..Preservation of the polypeptide structure during storage of the vaccine will also be addressed by formulating the vaccine candidate in protein stabilizinq recipients. ..
  32. Formulated Patch for Topical Influenza Vaccine
    Gregory Glenn; Fiscal Year: 2004
    ..Needle-free may also aid in the extension of use of a flu patch into the pediatric population where influenza immunization is now recommended by the ACIP and will be a subsequent goal of this development program. ..
  33. Time-lines of neural degeneration in ALS-PDC mouse model
    Christopher A Shaw; Fiscal Year: 2010
    ..These data will provide therapeutic targets to prevent or halt the progression of neurodegeneration. ..
  34. Modulation of B-cell tolerance by coreceptor molecules
    ROBERT RICKERT; Fiscal Year: 2005
    ....
  35. Community Environmental Health Research: Finding Meaning
    David Ozonoff; Fiscal Year: 2006
    ..4) Establish mechanisms for forging new and on-going community-researcher relationships. ..
  36. Mining slime mold for susceptibility genes to fungi
    Arturo Casadevall; Fiscal Year: 2005
    ..discoideum system will lead to the identification of genetic pathways that are not immediately obvious from standard fungal-macrophage experiments. ..
  37. Development of a mucosally administered trivalent serotype A,B, E botulinum va
    Robert Brey; Fiscal Year: 2006
    ..At the end of Phase II, we expect to have identified a vaccine to advance to clinical studies. [unreadable] [unreadable] [unreadable]..
  38. ORAL BDP FOR THE TREATMENT OF GI GVHD
    Robert Brey; Fiscal Year: 2005
    ..Abstract Not Provided ..
  39. Anthrax Immune Globulin to Prevent & Treat Anthrax: Clinical Development
    Robert Hopkins; Fiscal Year: 2006
    ..More information about Emergent BioSolutions and its subsidiaries can be found at www.ebsi.com. [unreadable] [unreadable] [unreadable]..
  40. Development of a New Tularemia Vaccine
    Mingtao Zeng; Fiscal Year: 2006
    ..Since no previous research has shown that genetic immunization with adenovirus or plasmid vectors could elicit protective immunity to F. tularensis, the proposed project is exploratory and developmental in nature. ..
  41. C3d-PA: efficacy & cellular basis as an anthrax vaccine
    ROBERT RICKERT; Fiscal Year: 2005
    ..Pending completion of the proposed work outlined in this R21 application, a series of experiments involving anthrax challenge models would seem appropriate. ..
  42. BioThrax Schedule Optimization for Post-Exposure Prophylaxis of Anthrax
    Robert Hopkins; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  43. MOLECULAR CHARACTERIZATION OF C NEOFORMANS ANTIBODIES
    Arturo Casadevall; Fiscal Year: 2006
    ..These studies are expected to yield new insights on fundamental aspects of antibody function as well as practical information for the development of second generation antibody reagents for human therapy. ..
  44. Transcutaneous Immunization for an Anthrax Vaccine
    Gregory Glenn; Fiscal Year: 2005
    ....
  45. STATISTICAL METHODS IN AIDS RESEARCH
    Ronald Brookmeyer; Fiscal Year: 2001
    ..The methods will be applied to the ALIVE study. ..
  46. Multi-component and easily administrated anthrax vaccine
    Mingtao Zeng; Fiscal Year: 2003
    ..Specific Aim #2: To compare the systemic and mucosal immunity elicited by the vaccine developed in #1 through intranasal inoculation with that elicited by plasmid expression vectors through intramuscular injection. ..
  47. Genetic immunization against pneumococcal disease
    Mingtao Zeng; Fiscal Year: 2004
    ....